Medicus Pharma grants CMO 1.47M shares, options

Medicus Pharma’s chief medical officer received a stock option and over 1.4 million common shares as equity compensation on September 4, 2026.

Rhea-AI Filing Summary

Medicus Pharma Ltd. (MDCX) reported that Chief Medical Officer Mehmud Faisal received an equity award on September 4, 2026. He was granted a stock option to acquire 250,000 Common Shares at an exercise price of $0.1705 per share, expiring September 4, 2031, vesting quarterly in four equal installments over one year. He also received a direct grant of 1,470,588 Common Shares at $0.1705 per share, bringing his direct common share holdings to 1,470,588 shares. No Rule 10b5-1 trading plan is reported for these awards.

Insider Trade Summary

Grant/Award: 1,720,588 shares

Grant/Award 2 txns

Insider Mehmud Faisal

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	250,000	$0.00	$0.00
Grant/Award	Common Shares, no par value	1,470,588	$0.1705	$251K

Holdings After Transaction: Stock Option (right to buy) — 250,000 contracts (Direct); Common Shares, no par value — 1,470,588 shares (Direct)

Footnotes (1)

1. F1. The option was granted on September 4, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

Key Figures

Stock option shares: 250,000 shares Stock option exercise price: $0.1705 per share Option expiration date: September 4, 2031 +4 more

7 metrics

Stock option shares 250,000 shares Option to buy Common Shares granted to the chief medical officer on September 4, 2026

Stock option exercise price $0.1705 per share Exercise price for the 250,000-share option granted September 4, 2026

Option expiration date September 4, 2031 Expiration of the 250,000-share stock option

Common Shares granted 1,470,588 shares Direct grant of Common Shares to the chief medical officer on September 4, 2026

Grant price for Common Shares $0.1705 per share Reported price for the 1,470,588 Common Shares granted September 4, 2026

Common Shares held after grant 1,470,588 shares Direct Common Share holdings of the chief medical officer following the reported transaction

Vesting schedule Four quarterly installments over one year Schedule for vesting of the 250,000-share stock option

Key Terms

Stock Option (right to buy), Common Shares, no par value, vest quarterly in four equal installments

3 terms

Stock Option (right to buy) financial

"Stock Option (right to buy)"

Common Shares, no par value financial

"Common Shares, no par value"

vest quarterly in four equal installments financial

"The option is scheduled to vest quarterly in four equal installments over one year."

FAQ

What equity awards did MDCX grant to Chief Medical Officer Mehmud Faisal?

Medicus Pharma granted Mehmud Faisal a stock option for 250,000 Common Shares at $0.1705 per share, expiring September 4, 2031, plus a direct grant of 1,470,588 Common Shares at $0.1705 per share on September 4, 2026.

How many Medicus Pharma (MDCX) common shares does Mehmud Faisal hold after this Form 4?

After the reported grant, Mehmud Faisal directly holds 1,470,588 Common Shares of Medicus Pharma Ltd., as of the transactions on September 4, 2026.

What are the terms of the new stock option reported for MDCX’s chief medical officer?

The stock option covers 250,000 Common Shares at an exercise price of $0.1705 per share, was granted on September 4, 2026, is scheduled to vest quarterly in four equal installments over one year, and expires on September 4, 2031.

Were the MDCX equity awards to Mehmud Faisal made under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with the equity awards granted to Mehmud Faisal on September 4, 2026.

What price was used for the common share grant to the MDCX chief medical officer?

The direct grant of 1,470,588 Common Shares to Mehmud Faisal on September 4, 2026 was reported at a price of $0.1705 per share.

Is the stock option granted to MDCX’s chief medical officer currently exercisable?

The option is scheduled to vest quarterly in four equal installments over one year from the grant date of September 4, 2026, so exercisability follows that vesting schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 05:01 PM Accepted by SEC EDGAR 09/08/2026 - 05:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mehmud Faisal

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares, no par value	09/04/2026		A		1,470,588	A	$0.1705	1,470,588	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.1705	09/04/2026		A		250,000		(1)	09/04/2031	Common Shares	250,000	$0	250,000	D

Explanation of Responses:

1. The option was granted on September 4, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

	/s/ Raza Bokhari, as Attorney-in-Fact, for Faisal Mehmud	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)